Metabolic Syndrome in Lean vs Obese Polycystic Ovarian Syndrome (PCOS) Phenotype
Abstract
Background/Aim: Polycystic ovarian syndrome (PCOS) is the most common metabolic, hormonal and endocrinological condition. Compared to lean, obese PCOS women are more likely to experience infertility, irregular menstruation, acanthosis and hirsutism. Aim of this study was to investigate the prevalence of metabolic syndrome in lean and obese PCOS patients as well as its correlation with age, body mass index (BMI) and obesity.
Methods: The 450 research participants in the cross-sectional study visited the tertiary care hospital. The individuals were chosen using the updated Rotterdam criteria and then divided into lean and obese groups according to their BMI. Clinical, biochemical, anthropometric, metabolic and demographic information about the patients were assessed and compared.
Results: The average age of obese patients was 29.8 ± 8.47 years, whereas the average age of lean patients was 24.8 ± 7.07 years. Obese PCOS individuals had significantly higher levels of all examined parameters, including age, height, weight, WHR, hip and waist circumferences and BMI. Obese people were significantly more likely than thin people to have clinical parameters such infertility, alopecia, hirsutism, acanthosis and irregular menstruation. When comparing biochemical parameters such total testosterone (TT), luteinising hormone (LH): follicle stimulating hormone (FSH) ratio, thyroid stimulating hormone (TSH), dehydroepiandrosterone sulphate (DHEAS), the fasting oral glucose tolerance test (OGTT) and blood pressure, there were significant differences between PCOS patients who were thin and obese. Compared to lean individuals, obese patients showed higher levels of the lipid profile (p < 0.001). Metabolic syndrome was far more common in obese PCOS patients than in lean ones.
Conclusion: Study showed that both lean and obese persons might have metabolic syndrome. Consequently, all PCOS patients require monitoring for cardio-metabolic risk, irrespective of age, weight, or BMI.
References
Shukla A, Rasquin LI, Anastasopoulou C. Polycystic ovarian syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [Cited: 22-Jul-2025]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459251/.
Moulana M. Androgen induced cardiovascular risk in polycystic ovary syndrome: the role of T lymphocytes. Life. 2023 Apr 14;13(4):1010. doi: 10.3390/life13041010.
World Health Organization (WHO). Polycystic ovary syndrome [Internet]. 7 Feb 2025. [Cited: 22-Jul-2025]. Available from: https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome.
Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, et al. Polycystic ovary syndrome: etiology, current management, and future therapeutics. J Clin Med. 2023 Feb 11;12(4):1454. doi: 10.3390/jcm12041454.
Bai H, Ding H, Wang M. Polycystic ovary syndrome (PCOS): symptoms, causes, and treatment. Clin Exp Obstet Gynecol. 2024 May 21;51(5). doi: 10.31083/j.ceog5105126.
Li J, Huang Y, Xu S, Wang Y. Sleep disturbances and female infertility: a systematic review. BMC Womens Health. 2024 Dec 20;24(1). doi: 10.1186/s12905-024-03508-y.
Kiran Z. Diagnostic criteria for polycystic ovary syndrome. In: Rehman R, Sheik A, Eds. Polycystic Ovary Syndrome. Amsterdam: Elsevier 2024. p.61-74. doi: 10.1016/B978-0-323-87932-3.00018-9.
Di Lorenzo M, Cacciapuoti N, Lonardo MS, Nasti G, Gautiero C, Belfiore A, et al. Pathophysiology and nutritional approaches in polycystic ovary syndrome (PCOS): a comprehensive review. Curr Nutr Rep. 2023 May 22;12(3):527-44. doi: 10.1007/s13668-023-00479-8.
Barber TM, Hanson P, Weickert MO, Franks S. Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health. 2019 Jan;13:1179558119874042. doi: 10.1177/1179558119874042.
Unluhizarci K, Karaca Z, Kelestimur F. Role of insulin and insulin resistance in androgen excess disorders. World J Diabetes. 2021 May 15;12(5):616-629. doi: 10.4239/wjd.v12.i5.616.
Barrea L, Frias Toral E, Verde L, Ceriani F, Cucalón G, Garcia Velasquez E, et al. PCOS and nutritional approaches: differences between lean and obese phenotype. Metabolism Open. 2021 Dec;12:100123. doi: 10.1016/j.metop.2021.100123.
Sanchez Garrido MA, Tena Sempere M. Metabolic dysfunction in polycystic ovary syndrome: pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020 May;35:100937. doi: 10.1016/j.molmet.2020.01.001.
Hirschberg AL. Hyperandrogenism and cardiometabolic risk in pre and postmenopausal women—what is the evidence? J Clin Endocrinol Metab. 2023 Oct 27;109(5):1202-13. doi: 10.1210/clinem/dgad590.
Chen W, Pang Y. Metabolic syndrome and PCOS: pathogenesis and the role of metabolites. Metabolites. 2021 Dec 14;11(12):869. doi: 10.3390/metabo11120869.
Amer Ali E, AL Jedda WA, AL Khateeb SMJ, AL Samarriae AY. The association between serum nesfatin 1 level and body mass index in Iraqi patients with polycystic ovary syndrome (PCOS). Indian J Forensic Med Toxicol. 2021 Mar 24;15(2):1490-5. doi: 10.37506/ijfmt.v15i2.14549.
Hamed EA, Sayyed HG, Abbas AM, Abdel Gaber MM, Abd El Aleem HM. Nesfatin 1, dopamine, and NADPH levels in infertile women with polycystic ovary syndrome: is there a relationship between their levels and metabolic and hormonal variables. J Reprod Infertil. 2022 Jul 11;23(3). doi: 10.18502/jri.v23i3.10006.
Abdelazim I, Alanwar A, AbuFaza M, Amer O, Bekmukhambetov Y, Zhurabekova G, et al. Elevated and diagnostic androgens of polycystic ovary syndrome. Menopausal Rev. 2020;19(1):1-5. doi: 10.5114/pm.2020.95293.
Amisi CA. Markers of insulin resistance in polycystic ovary syndrome women: an update. World J Diabetes. 2022 Mar 15;13(3):129-49. doi: 10.4239/wjd.v13.i3.129.
Sharma A, Sarwal Y, Devi NK, Saraswathy KN. Polycystic ovary syndrome prevalence and associated sociodemographic risk factors: a study among young adults in Delhi NCR, India. Reprod Health. 2025 Apr 28;22(1). doi: 10.1186/s12978-025-02019-9.
Zaeemzadeh N, Jahanian Sadatmahalleh S, Ziaei S, Kazemnejad A, Mottaghi A, Mohamadzadeh N, et al. Prevalence of metabolic syndrome in four phenotypes of PCOS and its relationship with androgenic components among Iranian women: a cross sectional study. Int J Reprod BioMed. 2020 May 5;18(4):253-64. doi: 10.18502/ijrm.v13i4.6888.
Karee M, Gundabattula SR, Sashi L, Boorugu H, Chowdhury A. Prevalence of metabolic syndrome in women with polycystic ovary syndrome and the factors associated: a cross sectional study at a tertiary care center in Hyderabad, south eastern India. Diabetes Metab Syndr. 2020 Jul;14(4):583-7. doi: 10.1016/j.dsx.2020.05.006.
Kaur R, Kaur M. Evaluation of potential association of metabolic syndrome in obese and non obese PCOS women. Middle East Fertil Soc J. 2024 Jan 26;29(1). doi: 10.1186/s43043-024-00170-0.
Kayali S, Chitra T, Kamalanathan S, Nandeesha H. Assessment of metabolic syndrome in infertile women with polycystic ovary syndrome in a rural population of South India: a cross sectional study. Int J Reprod BioMed. 2022 Apr 21;20(3):161-8. doi: 10.18502/ijrm.v20i3.10707.
Dadachanji R, Patil A, Joshi B, Mukherjee S. Elucidating the impact of obesity on hormonal and metabolic perturbations in polycystic ovary syndrome phenotypes in Indian women. PLoS One. 2021 Feb 26;16(2):e0246862. doi: 10.1371/journal.pone.0246862.
Varghese J, Kantharaju S, Thunga S, Joseph N, Singh P. Prevalence and predictors of metabolic syndrome in women with polycystic ovarian syndrome— a study from southern India. Int J Reprod Contracept Obstet Gynecol. 2015;1:113-8. doi: 10.5455/2320-1770.ijrcog20150222.
Arunachalam R, Priya K, Brindha R, Parthiban K. Understanding metabolic patterns in polycystic ovary syndrome: comparing lean and obese women at a family medicine clinic. J Family Med Prim Care. 2024 May;13(5):1837-42. doi: 10.4103/jfmpc.jfmpc_1425_23.
Kim JJ. Obesity and polycystic ovary syndrome. J Obes Metab Syndr. 2024 Dec 20;33(4):289-301. doi: 10.7570/jomes24035.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).